Puma Biotechnology Inc. (PBYI)
Puma Biotechnology Inc. (PBYI) Stock Price, Analysis & Data
| Bid | 6.53 |
| Market Cap | 459.42M |
| Revenue (ttm) | 231.24M |
| Net Income (ttm) | 26.72M |
| Beta | 1.22 |
| EPS (ttm) | 0.51 |
| PE Ratio (ttm) | 17.45 |
| Forward PE | 25.43 |
| P/B (ttm) | 3.28 |
| P/S (ttm) | 1.99 |
| Earnings Date | Nov 5, 2026 |
| Ask | 11.35 |
| Volume | 347,580 |
| Avg. Volume (20D) | 310,014 |
| Open | 9.01 |
| Previous Close | 8.77 |
| Day's Range | 8.78 - 9.22 |
| 52-Week Range | 4.30 - 9.40 |
| Analyst | Hold |
| Price Target | 6 (-32.58%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib...
Financial Performance
In 2025, Puma Biotechnology's revenue was 228.37M, a decrease of -0.91% compared to the previous year's 230.47M. Earnings were 31.11M, an increase of 2.75%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for PBYI stock is "Hold". The 12-month stock price forecast is 6, which is downside of 32.58% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
